Literature DB >> 6166671

Partial purification and chemical characterization of macrophage cytotoxicity factor (MCF, MAF) and its separation from migration inhibitory factor (MIF).

E M Kniep, W Domzig, M L Lohmann-Matthes, B Kickhöfen.   

Abstract

Macrophage cytotoxicity factor (MCF) was purified in 3 consecutive steps including adsorption chromatography on Matrex Gel Red A, hydrophobic chromatography on phenylalanine-Sepharose, and isoelectric focusing. MCF was characterized as a protein with a m.w. of approximately 30,000 by gel filtration on Sephadex G-100 with 2 isoelectric points at 7.4 and 8.4 in the presence of urea. The unpurified supernatant was fairly stable provided that manipulations favoring adsorption to membrane materials used for dialysis or ultrafiltration were omitted. The partially purified preparation was highly unstable. Trypsin treatment did not affect MCF activity, whereas chymotrypsin destroyed it. Treatment with glycosidases and neuraminidase or cultivation of cells in the presence of 2-deoxy-D-glucose or tunicamycin did not impair the MCF activity. MCF was separated from migration inhibitory factor (MIF) by 2 methods: first, isoelectric focusing in the presence of urea, and second by gel filtration on Ultrogel. MCF could be separated from interferon by chromatography on poly(I)-Sepharose.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6166671

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Intracellular destruction of Leishmania tropica by macrophages activated with macrophage activating factor/interferon.

Authors:  R G Titus; A Kelso; J A Louis
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

Review 2.  Macrophage functions in antimicrobial defense.

Authors:  T Schaffner; H U Keller; M W Hess; H Cottier
Journal:  Klin Wochenschr       Date:  1982-07-15

Review 3.  The role of lymphokines in delayed-type hypersensitivity reactions.

Authors:  C L Geczy
Journal:  Springer Semin Immunopathol       Date:  1984

4.  Studies on macrophage-activating factor (MAF) in antitumor immune responses. II. Molecular characterization of MAF produced by the tumor-immune Lyt-1+2- T cell subset.

Authors:  H Nakajima; Y Izumi; S Sugihara; Y Satoh; S Isumi; T Gotoh; H Fujiwara; T Hamaoka
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

5.  The Bcg/Ity/Lsh locus: genetic transfer of resistance to infections in C57BL/6J mice transgenic for the Nramp1 Gly169 allele.

Authors:  G Govoni; S Vidal; S Gauthier; E Skamene; D Malo; P Gros
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

6.  Inhibition of Chlamydia psittaci in oxidatively active thioglycolate-elicited macrophages: distinction between lymphokine-mediated oxygen-dependent and oxygen-independent macrophage activation.

Authors:  G I Byrne; C L Faubion
Journal:  Infect Immun       Date:  1983-05       Impact factor: 3.441

7.  Modulation of the immune response to tumors by a novel synthetic compound, (4R)-3-benzoyl-N-[(1R)-1-phenylethyl]-4-thiazolidinecarboxamide (RS-0481).

Authors:  S Kurakata; M Tomatsu; M Arai; H Arai; A Hishinuma; H Kohno; K Kitamura; T Kobayashi; K Nomoto
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

8.  Macrophage activation: priming activity from a T-cell hybridoma is attributable to interferon-gamma.

Authors:  J L Pace; S W Russell; R D Schreiber; A Altman; D H Katz
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

9.  Definition of a specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and murine macrophages in vitro and its effect upon macrophages in vivo.

Authors:  R P Singh; R Patarca; J Schwartz; P Singh; H Cantor
Journal:  J Exp Med       Date:  1990-06-01       Impact factor: 14.307

10.  Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity.

Authors:  A Celada; P W Gray; E Rinderknecht; R D Schreiber
Journal:  J Exp Med       Date:  1984-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.